Several specific genetic and epigenetic alterations affecting the NRF2 and NOTCH pathways have been identified in many clinical cohorts of lung cancer patients, and they hold significant potential for improving patients’ stratification and guiding therapeutic decision [7]. This evidence concerns the gene NFE2L2 and lung cancer.